Beyond CD3: Harnessing Gamma Delta T-cells for Efficient Targeting Across Cancer & Autoimmunity
12:30 pm - Wednesday 16th September 2026
- Exploring gamma delta T cells as a differentiated immune effector population to overcome limitations associated with classical CD3-based T-cell engagers
- Solving the scarcity issue: Novel TCE design or mechanism to expand gamma-delta T-cells in vivo
- Leveraging preclinical evidence and clinical insight from gamma delta T-cell therapies to inform safety, efficacy, and broader applicability